Search research articles
Contact Us
Filters
Showing results (41-50 of 616) with videos related to
Page
of 62
Sort By:
The Kaohsiung Journal of Medical Sciences
|
July 6, 2016
Interference of diabetes on the association of γ-glutamyl transpeptidase to platelet ratio with liver fibrosis in chronic hepatitis C
Chung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu
Journal of Hepatology
|
November 23, 2020
EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues
Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
April 22, 2025
Reply to comment on "Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program"
Hung-Wei Wang, Cheng-Yuan Peng, Ming-Lung Yu
Hepatology (Baltimore, Md.)
|
March 4, 2014
A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C
Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Journal of Hepatology
|
November 15, 2016
Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lung Yu
Journal of Hepatology
|
August 30, 2021
Predicting portal thrombosis in cirrhosis: Some issues
Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Journal of Hepatology
|
September 7, 2021
An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously
Chia-Yen Dai, Ming-Lun Yeh, Ming-Lung Yu
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 5, 2018
Author response to "Cryptogenic hepatocellular carcinoma (HCC) had worse overall survival of disease than viral HCC patients"
Tomi W Jun, Mindie H Nguyen, Ming-Lung Yu
The Kaohsiung Journal of Medical Sciences
|
October 21, 2017
Reply to "cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation"
Pei-Chien Tsai, Ta-Wei Liu, Ming-Lung Yu
Alimentary Pharmacology & Therapeutics
|
May 25, 2026
Editorial: Liver and Non-Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang
Page
of 62
Search research articles
Search
Showing results (41-50 of 616) with videos related to
Sort By:
Page
of 62
The Kaohsiung Journal of Medical Sciences
|
July 6, 2016
Interference of diabetes on the association of γ-glutamyl transpeptidase to platelet ratio with liver fibrosis in chronic hepatitis C
Chung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu
Journal of Hepatology
|
November 23, 2020
EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues
Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
April 22, 2025
Reply to comment on "Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program"
Hung-Wei Wang, Cheng-Yuan Peng, Ming-Lung Yu
Hepatology (Baltimore, Md.)
|
March 4, 2014
A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C
Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Journal of Hepatology
|
November 15, 2016
Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lung Yu
Journal of Hepatology
|
August 30, 2021
Predicting portal thrombosis in cirrhosis: Some issues
Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Journal of Hepatology
|
September 7, 2021
An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously
Chia-Yen Dai, Ming-Lun Yeh, Ming-Lung Yu
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 5, 2018
Author response to "Cryptogenic hepatocellular carcinoma (HCC) had worse overall survival of disease than viral HCC patients"
Tomi W Jun, Mindie H Nguyen, Ming-Lung Yu
The Kaohsiung Journal of Medical Sciences
|
October 21, 2017
Reply to "cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation"
Pei-Chien Tsai, Ta-Wei Liu, Ming-Lung Yu
Alimentary Pharmacology & Therapeutics
|
May 25, 2026
Editorial: Liver and Non-Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang
Page
of 62